Skip to main content
XBIO
NASDAQ Life Sciences

Xenetic Q2 Royalty Revenue Up 12%, But Net Loss Widens to $0.9M

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$3.042
Mkt Cap
$6.53M
52W Low
$1.9
52W High
$13.93
52W Position info
60% above low
Off High info
78% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

XBIO sits 60% above its 52-week low of $1.9.

Summary

Xenetic Biosciences reported Q2 2026 results with royalty revenue rising 12% year-over-year to $0.7 million, driven by the Takeda sublicense. However, net loss widened to $0.9 million from $0.7 million a year earlier, as a 64% jump in G&A expenses—tied to legal costs from a strategic review—offset a 16% decline in R&D spending. This follows a strong Q1 that saw a 36% revenue increase and a nearly halved net loss, making the Q2 loss expansion a setback. The strategic review process and associated legal costs are a new headwind to watch, with no timeline provided for resolution.

At the time of this announcement, XBIO was trading at $3.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.5M. The 52-week trading range was $1.90 to $13.93. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

XBIO - Latest Insights

XBIO
Nov 12, 2026, 5:00 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.66
Real-time Price: $1.54 info
Change: -$0.120 (-7%) info
Market Cap: $3.608M info
XBIO
Sep 23, 2026, 5:20 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.47
Real-time Price: $1.54 info
Change: -$0.930 (-38%) info
Market Cap: $3.608M info
XBIO
Sep 16, 2026, 10:28 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $2.22
Real-time Price: $1.54 info
Change: -$0.6778 (-31%) info
Market Cap: $3.608M info
XBIO
Sep 16, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.27
Real-time Price: $1.54 info
Change: -$2.73 (-64%) info
Market Cap: $3.608M info
XBIO
Sep 16, 2026, 7:00 AM EDT
Source: ACCESS Newswire
Importance Score:
9
Price at Filing: $4.27
Real-time Price: $1.54 info
Change: -$2.73 (-64%) info
Market Cap: $3.608M info